Circulation. 2007;115:1440-1455
Published online before print March 7, 2007, doi: 10.1161/CIRCULATIONAHA.106.666800
Published online before print March 7, 2007, doi: 10.1161/CIRCULATIONAHA.106.666800
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1440-1455.)
© 2007 American Heart Association, Inc.
Controversies in Cardiovascular Medicine |
Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents
A Cause for Concern
From the University of Geneva, Geneva, Switzerland (E.C.); Groupe Hospitalier Bichat-Claude-Bernard, Paris, France (P.G.S.); and Cardiovascular Center, OLV Hospital, Aalst, Belgium (W.W.).
Correspondence to Edoardo Camenzind, MD, University of Geneva, 1 rue Michel-Servet, 1211 Geneva, Switzerland. E-mail edoardo@camenzind-cardio.net
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
Percutaneous coronary intervention has become the most frequently used method of myocardial revascularization.1,2 The advent of coronary stenting led to a significant decrease in the complications seen after balloon angioplasty, resulting in improved patient outcome.3,4 Yet, stented angioplasty has been plagued from the onset by early stent thrombosis (<30 days after index procedure) and late in-stent restenosis (ISR). Initially, stent thrombosis rates as high as 24% raised serious doubts as to the viability of the therapy.5 With the combined prescription of thienopyridines and aspirin for 4 to 8 weeks,6,7 together with proper stent deployment techniques,8 early stent thrombosis rates decreased to what was felt to be an unavoidable and acceptable 1% to 1.5%. At the same time, efforts to reduce the 30% late ISR rates through systemic pharmacological approaches remained unsuccessful until local radiation, a strong antiproliferative therapy, was applied to prevent or treat ISR.9–13 Vascular brachytherapy was the first illustration that delayed healing might portend an increased risk of thrombosis together with the expected reduction in restenosis. Indeed, stent thrombosis rates increased again up to 5.3%, and the time window of event occurrence was extended beyond 1 year so that the initial clinical benefit would eventually erode as time went by.13,14 Today, first-generation drug-eluting stents (gen1-DES: Cypher, Cordis, Johnson & Johnson, Miami Lakes, Fla [sirolimus-eluting stent, SES] and Taxus, Boston Scientific Corp, Natick, Mass [paclitaxel-eluting stent]) releasing an antiproliferative compound (sirolimus or paclitaxel, respectively) via a nonbioerodable polymer have been proved to reduce the incidence of ISR by up
This article has been cited by other articles:
 |
|
 |
|
  S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur. Heart J., November 2, 2009; 30(22): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Silber, A. Colombo, A. P. Banning, K. Hauptmann, J. Drzewiecki, E. Grube, D. Dudek, and D. S. Baim Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions Circulation, October 13, 2009; 120(15): 1498 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K J Harjai, C Shenoy, P Orshaw, and J Boura Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry Heart, October 1, 2009; 95(19): 1579 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Byrne, S Kufner, K Tiroch, S Massberg, K-L Laugwitz, A Birkmeier, S Schulz, J Mehilli, and for the Intracoronary Stenting and Angiographic Re Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart, September 15, 2009; 95(18): 1489 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study Eur. Heart J., September 1, 2009; 30(17): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill A Case Against Low-Volume Percutaneous Coronary Intervention Centers Circulation, August 18, 2009; 120(7): 546 - 548. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Waksman and R. Pakala Drug-Eluting Balloon: The Comeback Kid? Circ Cardiovasc Interv, August 1, 2009; 2(4): 352 - 358. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Sipido, A. Tedgui, S. D. Kristensen, G. Pasterkamp, H. Schunkert, M. Wehling, P. G. Steg, W. Eisert, F. Rademakers, B. Casadei, et al. Identifying needs and opportunities for advancing translational research in cardiovascular disease Cardiovasc Res, August 1, 2009; 83(3): 425 - 435. [Full Text] [PDF]
|
|
|
|
|
|
G. G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T. F. Luscher, and F. C. Tanner Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents Eur. Heart J., June 29, 2009; (2009) ehp259v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Park, Y.-H. Kim, D.-W. Park, S.-W. Lee, W.-J. Kim, J. Suh, S.-C. Yun, C. W. Lee, M.-K. Hong, J.-H. Lee, et al. Impact of Intravascular Ultrasound Guidance on Long-Term Mortality in Stenting for Unprotected Left Main Coronary Artery Stenosis Circ Cardiovasc Interv, June 1, 2009; 2(3): 167 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Douglas, J. M. Brennan, K. J. Anstrom, A. Sedrakyan, E. L. Eisenstein, G. Haque, D. Dai, D. F. Kong, B. Hammill, L. Curtis, et al. Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1629 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Chen, J. Hermiller, A. K. Sinha, M. Sturek, L. Zhu, and G. S. Kassab Effects of stent sizing on endothelial and vessel wall stress: potential mechanisms for in-stent restenosis J Appl Physiol, May 1, 2009; 106(5): 1686 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Shishehbor, S. J. Filby, A. K. Chhatriwalla, R. D. Christofferson, A. Jain, S. R. Kapadia, A. M. Lincoff, D. L. Bhatt, and S. G. Ellis Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Applegate, M. T. Sacrinty, M. A. Kutcher, R. M. Santos, S. K. Gandhi, and W. C. Little 3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Stahli, G. G. Camici, and F. C. Tanner Drug-eluting stent thrombosis Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 45 - 52. [Abstract] [PDF]
|
|
|
|
|
|
Ph. G. Steg, K. A.A. Fox, K. A. Eagle, M. Furman, F. Van de Werf, G. Montalescot, S. G. Goodman, A. Avezum, W. Huang, J. M. Gore, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events Eur. Heart J., February 1, 2009; 30(3): 321 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Garcia-Tejada, M. Velazquez, F. Hernandez, A. Albarran, S. Rodriguez, I. Gomez, J. Andreu, and J. Tascon Percutaneous Revascularization of Grafts Versus Native Coronary Arteries in Postcoronary Artery Bypass Graft Patients Angiology, February 1, 2009; 60(1): 60 - 66. [Abstract] [PDF]
|
|
|
|
|
|
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al. Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007 Eur. Heart J., January 2, 2009; 30(2): 152 - 161. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Shemin Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof? Circulation, December 2, 2008; 118(23): 2326 - 2329. [Full Text] [PDF]
|
|
|
|
|
|
M. Hamilos, J. Sarma, M. Ostojic, T. Cuisset, G. Sarno, N. Melikian, A. Ntalianis, O. Muller, E. Barbato, B. Beleslin, et al. Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses Circ Cardiovasc Interv, December 1, 2008; 1(3): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao Hybrid Cardiovascular Procedures J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Agostoni and F. V. d. Branden Drug eluting stents in patients with diabetes BMJ, August 29, 2008; 337(aug29_3): a1359 - a1359. [Full Text]
|
|
|
|
|
|
K. O. Niemela Biodegradable coating for drug-eluting stents--more than a facelift? Eur. Heart J., August 2, 2008; 29(16): 1930 - 1931. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Holmes Jr, P. S. Teirstein, L. Satler, M. H. Sketch Jr, J. J. Popma, L. Mauri, H. Wang, P. A. Schleckser, S. A. Cohen, and SISR Investigators 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 439 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents JAMA, June 25, 2008; 299(24): 2868 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Hamilos, M. Ostojic, B. Beleslin, D. Sagic, L. Mangovski, S. Stojkovic, M. Nedeljkovic, D. Orlic, B. Milosavljevic, D. Topic, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2123 - 2129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C. H. Pell, I. R. Starkey, et al. Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland J. Public Health Med., June 1, 2008; 30(2): 186 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Krucoff, D. J. Kereiakes, J. L. Petersen, R. Mehran, V. Hasselblad, A. J. Lansky, P. J. Fitzgerald, J. Garg, M. A. Turco, C. A. Simonton III, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1543 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Di Mario and P. Barlis Optical Coherence Tomography: A New Tool to Detect Tissue Coverage in Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 174 - 175. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jeremias and A. Kirtane Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention Ann Intern Med, February 5, 2008; 148(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saia, A. Marzocchi, and A. Branzi Review: The safety of drug-eluting stents Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52. [Abstract] [PDF]
|
|
|
|
|
|
D. Austin, J. P Pell, and K. G Oldroyd Drug-eluting stents: do the risks really outweigh the benefits? Heart, February 1, 2008; 94(2): 127 - 128. [Full Text] [PDF]
|
|
|
|
|
|
N Melikian and W Wijns Drug-eluting stents: a critique Heart, February 1, 2008; 94(2): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jabara, N. Chronos, D. Conway, W. Molema, and K. Robinson Evaluation of a novel slow-release Paclitaxel-eluting stent with a bioabsorbable polymeric surface coating. J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 81 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Buttner and F.-J. Neumann Peeling-Off Labels: Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2037 - 2038. [Full Text] [PDF]
|
|
|
|
|
|
B. Doyle, C. S. Rihal, C. J. O'Sullivan, R. J. Lennon, H. J. Wiste, M. Bell, J. Bresnahan, and D. R. Holmes Jr Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents Circulation, November 20, 2007; 116(21): 2391 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thomas Interventional cardiology and the medical devices industry: is there a conflict of interest? Heart, November 1, 2007; 93(11): 1351 - 1352. [Full Text] [PDF]
|
|
|
|
|
|
P. Agostoni, G. M. Sangiorgi, and G. G.L. Biondi-Zoccai Letter by Agostini et al Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern" Circulation, October 16, 2007; 116(16): e388 - e388. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, L. Mauri, and R. E. Kuntz Letter by Kereiakes et al Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern" Circulation, October 16, 2007; 116(16): e389 - e389. [Full Text] [PDF]
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns Response to Letter Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern" Circulation, October 16, 2007; 116(16): e390 - e390. [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Tu, J. Bowen, M. Chiu, D. T. Ko, P. C. Austin, Y. He, R. Hopkins, J.-E. Tarride, G. Blackhouse, C. Lazzam, et al. Effectiveness and Safety of Drug-Eluting Stents in Ontario N. Engl. J. Med., October 4, 2007; 357(14): 1393 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-G. Chassot, A. Delabays, and D. R. Spahn Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction Br. J. Anaesth., September 1, 2007; 99(3): 316 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, G. Van Langenhove, and DELAYED RRISC (Death and Events at Long-term follo Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial J. Am. Coll. Cardiol., July 17, 2007; 50(3): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, P. K. Shah, and G. A. Diamond As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting J. Am. Coll. Cardiol., July 10, 2007; 50(2): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jaffe and B. H. Strauss Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives J. Am. Coll. Cardiol., July 10, 2007; 50(2): 119 - 127. [Abstract] [Full Text] [PDF]
|
|